Wilderness Anaphylaxis - Epinephrine Field Management

Key Points

• IM epinephrine is the first and most important treatment for anaphylaxis.
• Do not delay epinephrine while waiting for hives, antihistamines, or evacuation.
• There are no absolute contraindications to epinephrine in true anaphylaxis.
• Repeat IM dosing when serious symptoms persist or recur.
• Antihistamines treat skin symptoms, not airway edema or shock.
• Albuterol is an adjunct for bronchospasm after epinephrine.
• Positioning matters because sudden standing during shock can worsen collapse.
• Improvement in the field does not eliminate the need for evacuation and follow-up.

Algorithm

1. Recognize rapid allergic symptoms with respiratory compromise, hypotension, or multisystem involvement.
2. Remove the trigger when safely possible and call or initiate evacuation.
3. Give IM epinephrine in the lateral thigh immediately.
4. Position the patient appropriately and support airway, breathing, and circulation.
5. Repeat IM epinephrine every 5 to 15 minutes for persistent severe symptoms.
6. Add oxygen, inhaled bronchodilator, and IV crystalloid when indicated and available.
7. Use antihistamines only as adjuncts for cutaneous symptoms.
8. Continue observation during evacuation and be prepared for recurrence.

Clinical Synopsis & Reasoning

Anaphylaxis is a clinical diagnosis. In a wilderness setting, common triggers include foods, Hymenoptera stings, medications, and latex. Sudden involvement of the skin or mucosa together with respiratory compromise or hypotension is highly suggestive, but skin findings can be absent. A rapid combination of symptoms from multiple systems after a likely allergen also supports the diagnosis. Do not wait for hives before treating stridor, wheeze, syncope, or shock after a plausible exposure.

Immediately stop or remove the trigger when this can be done safely, such as removing a bee stinger by the fastest practical method. Place a hypotensive patient supine with legs elevated when breathing allows; a vomiting or unconscious patient may require lateral positioning, while severe respiratory distress may require sitting. Sudden standing can worsen venous return and collapse. In remote environments, monitoring is limited, so repeated examination of voice, work of breathing, pulse, mental status, and perfusion is essential.

Intramuscular epinephrine in the lateral thigh is the primary treatment. There is no absolute contraindication when true anaphylaxis is suspected. Antihistamines may relieve itching or hives but do not treat airway edema or shock and must never delay epinephrine. Bronchodilators can supplement epinephrine for persistent bronchospasm. A person who improves still requires evacuation planning because symptoms can recur and definitive monitoring may be hours away.

Treatment Strategy & Disposition

Administer IM epinephrine promptly using an autoinjector or correctly prepared syringe. Adult autoinjectors commonly deliver 0.3 mg, while weight-appropriate pediatric devices are used in children; some adult patients may have 0.5 mg devices depending on region. Repeat IM epinephrine every 5 to 15 minutes when significant symptoms persist or recur, according to clinical response and available protocol. If the patient has severe shock despite repeated IM dosing, advanced providers may require IV epinephrine infusion in a monitored setting, not unmonitored IV boluses.

Provide oxygen when available and support ventilation. Use inhaled albuterol for persistent wheeze after epinephrine. For hypotension, start isotonic crystalloid because profound vasodilation and capillary leak can create large intravascular deficits. H1 antihistamines are second-line for skin symptoms. Corticosteroids have delayed onset and should not be relied on to prevent acute death or replace epinephrine.

Evacuate every patient with significant anaphylaxis, particularly those requiring more than one epinephrine dose, with hypotension, airway involvement, asthma, uncertain trigger, or remote access to care. Carry enough epinephrine for delayed evacuation when possible. After recovery, prescribe or replenish autoinjectors, provide an action plan, and arrange allergy evaluation for trigger identification and preventive strategies such as venom immunotherapy when appropriate.

Epidemiology / Risk Factors

• Foods, insect stings, and medications are common wilderness triggers.
• People with asthma and prior severe anaphylaxis are at higher risk of a dangerous reaction.
• Skin findings are common but can be absent in life-threatening anaphylaxis.
• Delayed access to EMS makes preparedness and early epinephrine especially important.

Investigations

Field Priorities

Pharmacology

Prognosis / Complications

• Most patients respond well when epinephrine is given early.
• Delayed epinephrine is associated with worse outcomes.
• Biphasic recurrence can occur after an apparently successful initial response.
• Refractory anaphylactic shock requires critical-care vasopressor support.

Patient Education / Counseling

• Carry two epinephrine doses when possible and keep them accessible rather than buried in a pack.
• Teach companions when and how to administer an autoinjector.
• Replace expired or used devices promptly.
• After a significant reaction, obtain allergy evaluation and a written emergency plan.
• Patients with venom allergy should discuss venom immunotherapy with an allergist because it can substantially reduce future risk.

Notes

Wilderness management differs mainly in logistics, not in the drug that saves lives. The longer the evacuation time, the more important it is to carry enough epinephrine, teach companions, and repeat treatment based on clinical response.

The WMS guidance emphasizes that epinephrine has no absolute contraindication in anaphylaxis. Concerns about tachycardia or transient hypertension should not delay treatment of airway compromise or shock.

References

1. Wilderness Medical Society Anaphylaxis Clinical Practice Guidance — Link
2. Wilderness Medical Society Clinical Practice Guidelines — Link